93. Primary biliary cholangitis Clinical trials / Disease details


Clinical trials : 282 Drugs : 245 - (DrugBank : 56) / Drug target genes : 35 - Drug target pathways : 113

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05239468
(ClinicalTrials.gov)
February 202228/1/2022Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Patients With PBCA Phase 2a, Double-Blind, Randomized, Active Controlled, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Bezafibrate Administered in Combination With Obeticholic Acid in Subjects With Primary Biliary CholangitisPrimary Biliary CholangitisDrug: Bezafibrate 100 MG;Drug: Bezafibrate 200 MG;Drug: Obeticholic Acid 5 MG;Drug: Obeticholic Acid placebo;Drug: Bezafibrate PlaceboIntercept PharmaceuticalsNULLRecruiting18 YearsN/AAll60Phase 2United States
2NCT04751188
(ClinicalTrials.gov)
October 2, 20205/2/2021A Study to Assess Efficacy and Safety of Bezafibrate in Patients With Primary Biliary CholangitisSafety and Efficacy of Bezafibrate Plus Ursodesoxicolic Acid in Patients With Primary Biliary Cholangitis Without ResponsePrimary Biliary CirrhosisDrug: Bezafibrate 200 MG Oral Tablet;Drug: Placebo;Drug: Ursodeoxycholic AcidInstituto Mexicano del Seguro SocialNULLActive, not recruiting18 Years65 YearsAll11Phase 3Mexico
3NCT04594694
(ClinicalTrials.gov)
October 2, 201914/7/2020Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Patients With PBCA Phase 2, Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid Administered in Combination With Bezafibrate in Subjects With Primary Biliary Cholangitis Who Had an Inadequate Response or Who Were Unable to Tolerate Ursodeoxycholic AcidPrimary Biliary CholangitisDrug: Obeticholic acid;Drug: Bezafibrate 200 MG;Drug: OCA Placebo;Drug: Bezafibrate 200 mg Placebo;Drug: Bezafibrate 400 MG;Drug: Bezafibrate 400 mg PlaceboIntercept PharmaceuticalsNULLRecruiting18 YearsN/AAll75Phase 2Australia;Austria;Belgium;Croatia;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom